{
    "nctId": "NCT00426530",
    "briefTitle": "Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer",
    "officialTitle": "A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "To establish the feasible dose levels/regimens based on End-of-cycle-1 dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Female or male patients \u226518 years with WHO performance status \u2264 1\n* HER-2 overexpressing metastatic breast cancer cells confirmed by histology\n* Progressive disease on prior trastuzumab alone/or in combination with other anticancer agents, or relapsed any time after completion of this therapy\n* Patients neurologically stable with adequate bone marrow, liver and renal function\n\nExclusion criteria:\n\n* Patients receiving endocrine therapy for breast cancer \u2264 2 weeks prior to study treatment start\n* Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have received these \u2264 4 weeks prior to study treatment start or patients who have received lapatinib \u2264 2 weeks prior to study treatment start\n* Patients who have previously received vinorelbine or mTOR inhibitors\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}